Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PACB 
Pacific Biosciences of California (PACB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: PACB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.16
1 Year Target Price $2.16
| 5 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.45% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 477.59M USD | Price to earnings Ratio - | 1Y Target Price 2.16 |
Price to earnings Ratio - | 1Y Target Price 2.16 | ||
Volume (30-day avg) 14 | Beta 2.1 | 52 Weeks Range 0.85 - 2.72 | Updated Date 10/14/2025 |
52 Weeks Range 0.85 - 2.72 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -112.73% |
Management Effectiveness
Return on Assets (TTM) -33.28% | Return on Equity (TTM) -189.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 814015973 | Price to Sales(TTM) 3.06 |
Enterprise Value 814015973 | Price to Sales(TTM) 3.06 | ||
Enterprise Value to Revenue 5.21 | Enterprise Value to EBITDA -4.15 | Shares Outstanding 300370611 | Shares Floating 298123839 |
Shares Outstanding 300370611 | Shares Floating 298123839 | ||
Percent Insiders 7.88 | Percent Institutions 57.23 |
Upturn AI SWOT
Pacific Biosciences of California
Company Overview
History and Background
Pacific Biosciences of California, Inc. (PacBio) was founded in 2004. It pioneered Single Molecule, Real-Time (SMRT) Sequencing technology. Significant milestones include the release of the PacBio RS sequencer, Sequel systems, and Revio, continuously improving accuracy and throughput.
Core Business Areas
- Sequencing Systems: Development, manufacturing, and commercialization of sequencing systems for various applications.
- Consumables: Sale of consumables used with PacBio sequencing systems, including SMRT cells and sequencing reagents.
- Services: Provides instrument service and support, as well as sequencing services through service providers.
Leadership and Structure
Christian Henry is the President and CEO. The company has a typical corporate structure with departments covering R&D, Sales, Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- Market Share (%): Not available as an exact figure. However, PacBio is a major player in the long-read sequencing market, competing with Oxford Nanopore Technologies.
- Revio Sequencing System: High-throughput long-read sequencing platform. Revio has generated strong revenue growth for PacBio, and it helps scientists see further into biology for better insight and impactful discoveries. Competitors include Illumina, Oxford Nanopore Technologies.
- Market Share (%): Declining as customers upgrade to Revio, share is not specifically reported.
- Sequel II/IIe Systems: Earlier generation long-read sequencing platforms, still used in many labs. Competitors include Illumina, Oxford Nanopore Technologies.
- Consumables (SMRT Cells, Reagents): Essential for running PacBio sequencers. Revenue depends directly on instrument usage.
- Market Share (%): PacBio has 100% market share for consumables used on their own systems.
Market Dynamics
Industry Overview
The genomics market is growing rapidly, driven by increasing demand for DNA sequencing in research, diagnostics, and drug development. Long-read sequencing is increasingly important for applications requiring high accuracy, complex genome mapping, and structural variant detection.
Positioning
PacBio is a leader in long-read sequencing, known for high accuracy. It competes with Illumina and Oxford Nanopore Technologies.
Total Addressable Market (TAM)
The genomics market is estimated to be worth tens of billions of dollars, with long-read sequencing representing a significant and growing portion. PacBio is positioned to capture a larger share of this market with its advanced technology and increasing customer base.
Upturn SWOT Analysis
Strengths
- High accuracy long-read sequencing technology
- Strong brand recognition in long-read sequencing
- Revio platform generating significant momentum
- Established customer base in research institutions
Weaknesses
- Higher cost per base compared to short-read sequencing
- Reliance on capital equipment sales
- Lower throughput compared to short-read sequencing (though improving)
- Not yet profitable
Opportunities
- Expanding applications of long-read sequencing in clinical diagnostics
- Increasing adoption of long-read sequencing in drug discovery
- Strategic partnerships with other genomics companies
- Further technological advancements to improve throughput and reduce costs
Threats
- Intense competition from Illumina and Oxford Nanopore Technologies
- Potential for disruptive sequencing technologies to emerge
- Economic downturn impacting capital equipment budgets
- Regulatory hurdles for clinical applications
Competitors and Market Share
Key Competitors
- ILMN
- ONT.L
Competitive Landscape
PacBio's advantage is its high accuracy long reads and complete view of the genome. Illumina dominates the overall sequencing market with short-read sequencing and their ecosystem, whereas Oxford Nanopore Technologies offers real-time and scalable long-read sequencing.
Major Acquisitions
Circulomics
- Year: 2021
- Acquisition Price (USD millions): 80
- Strategic Rationale: Expanded PacBio's sample preparation workflow capabilities and increased efficiency with ultra-high molecular weight DNA extraction.
Growth Trajectory and Initiatives
Historical Growth: PacBio's growth has been uneven, with periods of rapid growth followed by periods of slower growth. The launch of the Revio system has revitalized growth.
Future Projections: Analyst estimates generally project continued revenue growth for PacBio, driven by increased adoption of long-read sequencing and the continued success of the Revio platform. Profitability is expected in the coming years.
Recent Initiatives: Recent initiatives include the launch of the Revio system, strategic partnerships with other companies, and expansion into new markets.
Summary
PacBio is a prominent player in the long-read sequencing market, driven by its high accuracy and the Revio system. While not yet profitable, revenue growth is accelerating. Competition remains intense, especially from Illumina. Continued innovation and strategic partnerships are crucial for maintaining its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacific Biosciences of California
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2010-10-27 | President, CEO & Director Mr. Christian O. Henry M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 575 | Website https://www.pacb.com |
Full time employees 575 | Website https://www.pacb.com | ||
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.